A Study of Patients Receiving High-Dose Rate Brachytherapy
Number: NCT00924027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
Number: NCT01581749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Albert DeNittis|Main Line Health Sponsor Trial Information Trial Location(s) and Contact(s): |
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
Number: NCT02040610 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
Number: NCT02334579 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
Number: NCT02600156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Number: NCT02643667 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Washington University School of Medicine|Pharmacyclics LLC. Sponsor Trial Information Trial Location(s) and Contact(s): |
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Number: NCT03424850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Washington University School of Medicine Sponsor Trial Information Trial Location(s) and Contact(s): |
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Number: NCT03496805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences Sponsor Trial Information Trial Location(s) and Contact(s): |
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
Number: NCT03525262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Texas Southwestern Medical Center|Boston Scientific Corporation Sponsor Trial Information Trial Location(s) and Contact(s): |
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance
Number: NCT03679260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Number: NCT03716739 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute|National Institute on Aging (NIA) Sponsor Trial Information Trial Location(s) and Contact(s): |
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Number: NCT03769766 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Number: NCT03821246 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Lawrence Fong|Genentech, Inc.|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s): |
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
Number: NCT04147806 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Albert Einstein College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s): |
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
Number: NCT04300855 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Prostate Imaging Using MRI +/- Contrast Enhancement
Number: NCT04571840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s): |
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
Number: NCT05424783 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |